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Introduction: Once-daily tiotropium Respimat 5 mg is an efficacious add-on therapy to inhaled
corticosteroids (ICS) with or without long-acting b2-agonists in patients with symptomatic
asthma. The objective of this study was to investigate whether the dosing regimen of tiotro-
pium (once- versus twice-daily), delivered via the Respimat SoftMist inhaler, affected 24-
h bronchodilator efficacy and safety versus placebo Respimat in patients with asthma whoAsthma Control Questionnaire; AM2þ, Asthma Monitor2þ device; AUC, area under the curve;
a uniform dosing interval t at steady state; AUC(0e24h),ss, area under the curve over 24 h at steady
ce interval; Cmax,ss, steady-state maximum plasma concentration; CV, coefficient of variation;
h at steady state (expressed as percentage of dose); FEV1, forced expiratory volume in 1 s; FEV1
in 1 s area under the curve from 0 to 24 h; FVC, forced vital capacity; ICS, inhaled corticosteroids;
V1(0e24h), peak forced expiratory volume in 1 s measured within 24 h of the last evening inhalation;
rning peak expiratory flow; PEFpm, evening peak expiratory flow; QD, once-daily; SD, standard de-
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bronchodilatorwere symptomatic despite medium-dose ICS therapy.
Methods: A randomised, double-blind, placebo-controlled, crossover study with 4-week treat-
ment periods of tiotropium 5 mg (once-daily, evening) and 2.5 mg (twice-daily, morning and
evening). The primary efficacy end point was forced expiratory volume in 1 s (FEV1) area under
the curve from 0 to 24 h (AUC)(0e24h) at the end of each treatment period. Secondary end
points included peak forced expiratory volume in 1 s measured within 24 h of the last evening
inhalation (peak FEV1(0e24h)), trough FEV1 measured prior to evening dosing, morning and eve-
ning peak expiratory flow (PEFam and PEFpm) and pharmacokinetic assessments.
Results: 94 patients were randomised (mean age 44.3 years; mean asthma duration 21.3 years)
and 89 (94.7%) completed the study. Significant and comparable bronchodilation was achieved
over a 24-h period with both tiotropium dosing regimens. FEV1 AUC(0e24h) response
(mean  standard error) was significantly greater with both tiotropium dosing regimens
(once-daily 5 mg: 158  24 mL; twice-daily 2.5 mg; 149  24 mL; both p < 0.01) when compared
with placebo. Improvements in peak FEV1(0e24h), trough FEV1 and pre-dose PEFam/pm with both
dosing regimens versus placebo were statistically significant (all p < 0.01), with no statistically
significant differences between the tiotropium treatment regimens. Total systemic exposure
and tolerability were comparable between treatment regimens.
Conclusions: Lung function improvements with tiotropium Respimat add-on to medium-dose
ICS were sustained and similar for once-daily 5 mg and twice-daily 2.5 mg, supporting tiotropium
Respimat 5 mg as a once-daily bronchodilator that provides efficacy over the whole 24-h
dosing interval in patients with symptomatic asthma.
ClinicalTrials.gov identifier: NCT01152450.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
International and national guidelines for the management
of asthma recommend inhaled corticosteroids (ICS) as the
first step for maintenance treatment of patients with
symptomatic asthma [1e3]. Increasing the ICS dose or
adding a long-acting b2-agonist (LABA), leukotriene modi-
fier or sustained-release theophylline to low-dose ICS are
options for patients who subsequently remain or become
symptomatic. However, despite these options, at least 40%
of patients with asthma remain symptomatic on currently
available maintenance therapies [4e6].
Multiple randomised, double-blind, Phase II and III clin-
ical studies have shown that once-daily tiotropium is an
efficacious and well-tolerated add-on therapy to ICS, with
or without a LABA, for patients with symptomatic asthma
[7e13]. In Phase II trials, tiotropium solution for inhalation
delivered via the Respimat SoftMist inhaler (Boehringer
Ingelheim, Ingelheim am Rhein, Germany) provided im-
provements in lung function at once-daily doses of 10 mg,
5 mg, 2.5 mg or 1.25 mg when compared with placebo
Respimat [8,9,11]. The 5 mg dose was consistently shown
to provide the largest improvement in lung function when
added to at least ICS, with no significant improvement in
forced expiratory volume in 1 s (FEV1) observed by
increasing the dose to 10 mg [9]. The 5 mg dose was there-
fore selected as the appropriate dosing regimen for addi-
tional Phase II and III trials. Long-term trials in patients with
symptomatic asthma have shown that once-daily tio-
tropium 5 mg increased the time to first severe exacerbation
and improved lung function when added to high-dose ICS
plus LABA [10]. In Phase II and III trials, tiotropium improved
lung function and symptoms, measured with the seven-question Asthma Control Questionnaire (ACQ-7), when
added to medium-dose ICS, and the treatment effects were
comparable with those observed with salmeterol [12e14].
The objective of the present placebo-controlled study
was to investigate whether the dosing regimen (once-daily
5 mg versus twice-daily 2.5 mg) of tiotropium affected 24-h
bronchodilator efficacy and safety in adult patients who
were symptomatic despite treatmentwithmedium-dose ICS.
Methods
Study design
This was a randomised, double-blind, placebo-controlled,
crossover, Phase II study (ClinicalTrials.gov identifier:
NCT01152450) (Fig. 1) conducted at 15 sites in five coun-
tries (Czech Republic, Estonia, Latvia, Austria and Ger-
many). Patients entered a 28-day screening period.
Subsequently, eligible patients were randomised to three 4-
week treatment periods, with no washout between treat-
ments, and with a 21-day follow-up period.
All study documentation was approved by the relevant
independent ethics committees. The study was performed in
accordance with the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation Tripartite Guideline for
Good Clinical Practice, and applicable regulatory re-
quirements. All patients providedwritten, informed consent.
Study treatment
Patients received once-daily tiotropium 5 mg in the evening
plus once-daily placebo in the morning, twice-daily
Figure 1 Study design. Visits 3, 5 and 7 were telephone visits. AM2þ, Asthma Monitor2þ device (eResearch Technology GmbH,
Estenfeld, Germany); BID, twice-daily dosing, morning and evening; ICS, inhaled corticosteroids; PEF, peak expiratory flow; QD,
once-daily dosing, evening.
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daily placebo in the morning and evening, all delivered via
the Respimat SoftMist inhaler. Patients continued
maintenance treatment with medium-dose ICS (defined as a
daily dose of budesonide 400e800 mg or equivalent)
throughout the study.
Medications permitted for the treatment of acute
asthma exacerbations during the study included salbutamol
metered-dose inhaler as needed (with a 8-h washout prior
to all visits including lung function tests), temporary in-
creases in the dose of ICS or addition of systemic steroids,
and short-acting theophylline.
Non-permitted maintenance medications after
screening (Visit 1) included systemic steroids, LABAs, anti-
cholinergics other than the study drug, methylxanthines,
anti-immunoglobulin E treatment, leukotriene modifiers
and cromones.
Study population
Inclusion criteria included: male or female patients aged
18e75 years; 3-month history of asthma with an initial
diagnosis before the age of 40 years, confirmed at screening
by FEV1 reversibility of 12% and 200 mL (10e15 min after
salbutamol 400 mg); symptomatic but stable with an ACQ-7
total score of 1.5 at screening (and prior to random-
isation); pre-bronchodilator FEV1 60% and 90% of pre-
dicted normal at screening; variability of absolute FEV1values from screening to randomisation within 30%. Pa-
tients must have received maintenance therapy with sta-
ble, medium-dose ICS, either alone or in a fixed-dose
combination with a LABA or short-acting b2-agonist, for 4
weeks prior to screening (Visit 1); however, LABA treatment
was not permitted during the study (from entering the 4-
week run-in period until completion of the third treat-
ment period) meaning that patients were switched to ICS
monotherapy at least 24 h prior to screening. Other inclu-
sion criteria included never smokers, or ex-smokers who
had stopped 1 years prior to enrolment and with a
smoking history of <10 pack-years. The main exclusion
criteria included a diagnosis of significant disease or lung
disease other than asthma (eg, chronic obstructive pulmo-
nary disease).
Study end points
All lung function end points were analysed as responses,
defined as the change from study baseline at randomisation
before the first inhalation of study drug. ACQ-7 total score
was analysed as an absolute value.
The primary efficacy end point was FEV1 area under the
curve (AUC) from 0 to 24 h (FEV1 AUC(0e24h)), measured
within 24 h of the last evening inhalation at the end of each
4-week treatment period.
Secondary lung function end points included peak FEV1,
measured within 24 h of the last evening inhalation at the
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FEV1, measured 10 min prior to the last evening inhalation
at the end of each 4-week period. Pre-dose morning and
evening peak expiratory flow (PEFam and PEFpm, respec-
tively) were evaluated based on the weekly mean of the
last week of each 4-week treatment period and were
measured at home using the Asthma Monitor2þ device
(AM2þ; eResearch Technology GmbH, Estenfeld, Ger-
many). ACQ-7 score was determined at the end of each 4-
week treatment period.
Pharmacokinetic end points included maximum plasma
concentration, AUC(0et),ss (area under the curve over a
uniform dosing interval t at steady state), AUC(0e24h),ss
(area under the curve over 24 h at steady state) and urinary
excretion evaluated in blood and urine samples collected
from a subset of patients at selected sites at the end of
each 4-week treatment period (pharmacokinetic steady
state).
Study assessments
Spirometry (MasterScope CT; eResearch Technology
GmbH) was conducted at all clinic visits. Lung function
testing started at approximately the same time of day
(30 min), with visits scheduled to enable the start of the
evening pre-dose tests between 5:50 pm and 7:50 pm. At
each time point, spirometric manoeuvres were conducted
in triplicate. The highest FEV1 from an acceptable
manoeuvre was recorded, along with the time.
At Visits 4, 6 and 8, at the end of each 4-week treatment
period, lung function tests started 10 min before evening
dosing of study drug. Subsequently, lung function tests
were performed at 30 min, 1 h, 2 h, 3 h, 4 h and 11 h 50 min
after inhalation of the last evening dose of study drug.
Morning dosing was performed 12 h after evening dosing,
and lung function tests were subsequently performed at
12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h and
23 h 50 min post-evening dosing. At Visits 3, 5 and 7 (Weeks
2, 6 and 10, respectively), patients were contacted by
telephone to record study drug adherence, concomitant
medications and adverse events.
Patients performed twice-daily PEF measurements at
approximately the same time of day before inhalation of
ICS and study drug using the AM2þ device at home. PEFam
measurement was performed shortly after waking. PEFpm
measurement was performed prior to administration of
maintenance ICS and trial medication. Patients performed
three manoeuvres with the AM2þ device while standing,
and the highest value was used for evaluation. ACQ-7 was
self-administered on paper at Visits 4, 6 and 8.
Safety and tolerability were assessed by the occurrence
of adverse events.
Statistical analyses
Efficacy data are reported for the full analysis set, defined
as all treated patients who had baseline data and at least
one on-treatment efficacy measurement after 4 weeks of
treatment within a treatment period. The pharmacoki-
netic subset was defined as all patients who provided
samples for the evaluation of the pharmacokineticsof tiotropium in blood and urine. Safety data are
reported for the treated set, defined as all randomised
patients who received at least one dose of study
medication.
Assuming a standard deviation of 220 mL for within-
patient difference of FEV1 AUC(0e24h), a sample size of 90
randomised patients to obtain 82 completed patients was
needed for a full crossover design to be able to detect a
treatment difference of 80 mL for FEV1 AUC(0e24h) with 90%
power. AUC was calculated by using the trapezoidal rule
divided by the observation time (24 h).
A step-wise testing of the null hypothesis for the
comparison of once-daily tiotropium 5 mg and then twice-
daily 2.5 mg versus placebo was used to control the prob-
ability of type I error. Testing was performed with
a Z 0.025 (one-sided). All means are presented as
adjusted means.
The pre-specified hypotheses were tested using a mixed
effect model with repeated measurements. The statistical
model included ‘treatment’ and ‘period’ as fixed effects
and ‘patient’ as a random effect. ‘Study baseline’, defined
as pre-treatment values measured at the randomisation
visit in the evening, was included as a covariate, which was
accomplished by using compound symmetry covariance
structure for within-patient variation. Adjusted mean
values as well as treatment contrasts were calculated
together with 95% confidence intervals and p values. A
mixed effect model with repeated measurements analysis,
as defined for the primary end point, was performed for all
secondary end points to compare both tiotropium dosing
regimens in an exploratory manner. For ACQ-7, study
baseline was defined as the Visit 2 score obtained prior to
the administration of the first dose of study drug. For PEFam
and PEFpm, only the last week of each treatment period was
evaluated.
Safety and tolerability, assessed by an analysis of
adverse events, were descriptive only.Results
Patients
A total of 182 patients were enrolled at 15 sites in five
countries (Czech Republic, Estonia, Latvia, Austria and
Germany). Of the enrolled patients, 94 were randomised
to treatment and included in the treated set (Fig. 2).
Ninety-two patients were included in the full analysis set
and 89 patients (94.7%) completed all three treatment
periods.
Baseline demographics and disease characteristics are
shown in Table 1. All patients were white and 58.5% were
female. Mean age was 44.3 years, mean duration of asthma
was 21.3 years, and most patients (83.0%) had never
smoked. In the 17% of patients who were ex-smokers, the
mean (standard deviation) number of pack-years was 5.3
(2.8). During the treatment period, all patients continued
their ICS medication: fluticasone (48.9%) and budesonide
(42.2%) were the most frequently used (mean budesonide
or equipotent dose  standard deviation at randomisation:
640  203 mg).
Figure 2 CONSORT diagram. Patients who failed screening (n Z 88) did not meet the pre-specified inclusion criteria.
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The dosing regimen of tiotropium did not affect 24-h
bronchodilator efficacy: both once- and twice-daily
dosing, providing a total daily dose of 5 mg, were equally
efficacious, with no statistically significant difference be-
tween treatment regimens.
Primary end point
Both tiotropium dosing regimens provided statistically sig-
nificant improvements in bronchodilation, versus placebo,
with an adjusted mean difference (standard error) in FEV1
AUC(0e24h) response of 158 (24) mL following once-daily
5 mg and 149 (24) mL following twice-daily 2.5 mg (both
p < 0.01) (Table 2). No statistically significant difference
between the two dosing regimens was observed (9  24 mL
[95% confidence interval 0.038 to 0.056]).
Secondary end points
Both tiotropium dosing regimens provided comparable
improvements in peak FEV1(0e24h) and trough FEV1 re-
sponses that were statistically significant versus placebo
(all p < 0.01) (Table 2), with no statistically significant
difference observed between the mean values for the two
dosing regimens. The profile of FEV1 response over 24 h was
comparable between treatment regimens, with statisti-
cally significant improvements observed with both tio-
tropium treatment regimens, versus placebo, during
daytime and night-time and at all time points (all p < 0.01)
(Fig. 3).PEFam and PEFpm responses at the end of each treatment
period (calculated as weekly means) were significantly
greater for once-daily tiotropium 5 mg and twice-daily tio-
tropium 2.5 mg, each compared with placebo (both p< 0.01)
(Table 3). The responses were equally efficacious with either
tiotropium dosing regimen, with no statistically significant
mean difference observed between treatment regimens.
For mean ACQ-7 score, a statistically significant
improvement (decrease) was reported for both tiotropium
treatment regimens when compared with placebo (once-
daily 5 mg: 0.274, p < 0.01; twice-daily 2.5 mg: 0.190,
p < 0.01). Improvements in mean ACQ-7 score were com-
parable between the two tiotropium dosing regimens.
Pharmacokinetics
Pharmacokinetic parameters assessed at steady state are
shown in Table 4. Total exposure was comparable between
the two tiotropium dosing regimens: the once-daily 5 mg
AUC(0et),ss (24-h dosing interval) was 47.9 pg$h/mL; the
twice-daily 2.5 mg AUC(0e24h),ss was 52.0 pg$h/mL (in this
scenario, the parameters AUC(0et),ss and AUC(0e24h),ss are
approximately equivalent as the once-daily dosing interval
is 24 h). However, as expected, maximum plasma concen-
tration values for morning and evening dosing were lower
(39%e47%, respectively) for twice-daily tiotropium 2.5 mg
than for once-daily tiotropium 5 mg evening dosing. The
cumulative urinary excretion of tiotropium over 24 h was
similar for both dosing regimens at steady state (urinary
excretion over 24 h at steady state: 13.1% and 13.0% of the
Table 1 Baseline patient demographics and disease
characteristics.a
Patients
(n Z 94)
Sex, n (%)
Male 39 (41.5)
Female 55 (58.5)
Age, years 44.3  13.2
Smoking status, n (%)
Never smoked 78 (83.0)
Ex-smoker 16 (17.0)
Smoker 0
Smoking history, pack-years 5.3 (2.8)
Duration of asthma, years 21.3 (13.1)
FEV1
% of predicted value pre-bronchodilation
at screeningb
73.4  7.9
% of predicted value post-bronchodilation
at screeningb
90.1  10.6
Reversibility, mLb 551  302
% reversibilityb 23.0  10.9
Pre-dose at study baseline, mLc 2513  697
FVC
Pre-dose at study baseline, mLc 3943  1009
% of predicted value pre-dose
at study baselinec
101.5  14.1
FEV1/FVC ratio pre-dose at study
baseline,%c
64.1  9.2
PEF, L/mind
PEFam 373  124
PEFpm 396  126
LABA use, n (%)e 75 (79.8)
ICS dose of stable maintenance
treatment, mgf,g
640  203
ACQ-7 total scorec 2.317  0.504
ACQ-7, seven-question Asthma Control Questionnaire; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity; ICS,
inhaled corticosteroids; LABA, long-acting b2-agonist; PEF, peak
expiratory flow; PEFam, morning peak expiratory flow; PEFpm,
evening peak expiratory flow.
a All values are for treated set except for PEF values, which
are for the full analysis set; all values are mean (standard
deviation) except for sex, smoking status and LABA use.
b Visit 1 (screening), measured 10e15 min after inhalation of
four puffs of salbutamol (100 mg per actuation).
c Visit 2 (randomisation), measured 10 min prior to inhalation
of the first dose of study drug.
d Measured using the Asthma Monitor2þ device.
e Within last 3 months prior to Visit 1 (screening).
f Budesonide equipotent dose.
g Measured at Visit 2 (randomisation).
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respectively).
Adverse events
The overall occurrence of adverse events was balanced
between both tiotropium dosing regimens and placebo(Table 5). The most frequently reported adverse events
were headache, nasopharyngitis, diarrhoea and dry mouth.
Two patients, both when receiving placebo, discontinued
the study due to the occurrence of adverse events (hyper-
tension in one patient and diarrhoea in one patient).
Drug-related adverse events were infrequent and
occurred in four patients (4.4%) receiving once-daily tio-
tropium 5 mg (one patient with sinus tachycardia and
adverse drug reaction after salbutamol intake, one patient
with cough and dry mouth, one patient with dry mouth and
dry throat, and one patient with nasal dryness and dry
mouth), three patients (3.3%) receiving twice-daily tio-
tropium 2.5 mg (two patients with dysphonia and one pa-
tient with dry mouth) and three patients receiving placebo
(one patient with cough, one patient with dysphonia, dry
mouth and nasal dryness, and one patient with nasal dry-
ness). The patient who experienced sinus tachycardia and
adverse drug reaction after salbutamol intake, while
receiving once-daily tiotropium 5 mg, was also reported as
having moderate supraventricular tachycardia, severe hy-
pertensive crisis (also considered a serious adverse event)
and moderate hypertension, all while receiving placebo;
these events were not considered drug-related.
Serious adverse events occurred in two patients
receiving once-daily tiotropium 5 mg and one patient
receiving placebo, all of which required hospitalisation.
One patient receiving once-daily tiotropium 5 mg reported
pain and oedema in the leg, which was diagnosed as venous
thrombosis. Another patient receiving once-daily tio-
tropium 5 mg was hospitalised due to a road traffic acci-
dent, with haemorrhage and fractured ribs. One patient
receiving placebo experienced a hypertensive crisis
(blood pressure 230/100 mm Hg). None of the serious
adverse events was considered drug-related. There were no
deaths.Discussion
The results of this study show that once-daily tiotropium
5 mg and twice-daily 2.5 mg, each as add-on to medium-dose
ICS, provide significantly greater bronchodilation when
compared with placebo as add-on to medium-dose ICS in
patients with moderate symptomatic asthma. The
improved bronchodilator efficacy with both tiotropium
dosing regimens for the primary end point (FEV1 AUC(0e24h)
response) and secondary end points (peak FEV1(0e24h),
trough FEV1, PEFam and PEFpm responses) was consistently
statistically significant versus placebo. For all end points,
the responses were equally efficacious with either tio-
tropium dose, with no statistically significant difference
observed between dosing regimens. The systemic exposure
of tiotropium, based on renal excretion, was comparable
between the once-daily and twice-daily dosing regimens.
The overall occurrence of adverse events was comparable
between all treatment groups and similar to previously
reported studies [8e11,13]. These results indicate that no
advantages are gained following twice-daily dosing of tio-
tropium 2.5 mg, rather than once-daily tiotropium 5 mg
dosing, and support once-daily tiotropium 5 mg as an
appropriate dosing regimen in patients with symptomatic
asthma.
Table 2 FEV1 AUC(0e24h), peak FEV1(0e24h) and trough FEV1 responses.
Treatment n Adjusted mean responsea Adjusted mean
difference versus
placebo Respimata
p valueb
Mean  SE Mean  SE 95% CI
Primary end point
FEV1 AUC(0e24h), mL
c
Once-daily tiotropium Respimat 5 mg 90 250  44 158  24 111e205 < 0.01
Twice-daily tiotropium Respimat 2.5 mg 89 241  44 149  24 102e196 < 0.01
Placebo Respimat 90 91  43
Secondary end points
Peak FEV1(0e24h), mL
Once-daily tiotropium Respimat 5 mg 90 468  45 131  24 84e179 < 0.01
Twice-daily tiotropium Respimat 2.5 mg 89 469  45 132  24 84e179 < 0.01
Placebo Respimat 90 337  45
Trough FEV1, mL
Once-daily tiotropium Respimat 5 mg 90 275  44 133  29 74e191 < 0.01
Twice-daily tiotropium Respimat 2.5 mg 89 254  44 111  30 53e170 < 0.01
Placebo Respimat 90 143  44
Full analysis set. At study baseline (randomisation, Visit 2), mean FEV1 in the full analysis set was 2524 mL (standard deviation 699 mL).
CI, confidence interval; FEV1, forced expiratory volume in 1 s; FEV1 AUC(0e24h), forced expiratory volume in 1 s area under the curve from
0 to 24 h; peak FEV1(0e24h), peak forced expiratory volume in 1 s measured within 24 h of the last evening inhalation; SE, standard error.
a Adjusted for treatment, period, patient and study baseline. Response is defined as the change from the study baseline at ran-
domisation before the first inhalation of study drug.
b Superiority for tiotropium Respimat versus placebo Respimat.
c Response is defined as mean area under the 24-h FEV1 curve minus study baseline.
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studies in similar patient populations, which show that
once-daily tiotropium 5 mg add-on to medium-dose ICS is an
efficacious bronchodilator with a safety profile comparable
with that of placebo [8,11,13]. They are also consistent
with findings in patients with more severe disease, treatedFigure 3 FEV1 response over 24 h. Time 0 h is 10 min prior to
evening dosing. Assessment of the full analysis set at the end of
each treatment period. At study baseline (randomisation, visit
2), mean FEV1 was 2524 mL (standard deviation 699 mL). FEV1,
forced expiratory volume in 1 s.with tiotropium 5 mg add-on to ICS plus LABA maintenance
therapy [10].
Further, the magnitude of the effect size for FEV1
AUC(0e24h) and trough FEV1 achieved with evening dosing of
tiotropium in the present study is also comparable with that
reported for evening dosing of a LABA (vilanterol) in similar
populations, when added to background ICS [15,16]. In our
study, where all treatments were added on to medium-dose
ICS, evening dosing with tiotropium 5 mg resulted in a mean
increase in FEV1 AUC(0e24h) and trough FEV1 of 250 mL and
275 mL, respectively, versus baseline and 158 mL and
133 mL, respectively, versus placebo. In a study of vilan-
terol as add-on to medium-dose ICS in adolescents and
adults with symptomatic asthma despite ICS therapy, a
once-daily evening dose of vilanterol 25 mg resulted in a
mean increase in FEV1 AUC(0e24h) of 165 mL versus placebo
plus ICS (no data versus baseline) and trough FEV1 of 269 mL
and 121 mL versus baseline and placebo plus ICS, respec-
tively [15]. In a second study of vilanterol as add-on to
medium- or high-dose ICS in adults with symptomatic
asthma despite ICS therapy, a once-daily evening dose of
vilanterol 25 mg resulted in a mean increase in FEV1
AUC(0e24h) of 185 mL and trough FEV1 of 125 mL versus
placebo plus ICS (no data versus baseline) [16].
Both tiotropium dosing regimens resulted in a statisti-
cally significant improvement in asthma control versus
placebo, as assessed by ACQ-7 score, which did not reach
clinical significance, as would be expected in a study of this
design and duration. The ability to draw firm conclusions
from the analysis of ACQ-7 scores is limited in this study by
the crossover design and the relatively short, 4-week,
treatment periods. An investigation of ACQ-7 responder
Table 3 PEFam and PEFpm responses.
Treatment n Adjusted mean
responsea
Adjusted mean difference
versus placebo Respimata
p value
Mean  SE Mean  SE 95% CI
Pre-dose PEFam, L/min
Once-daily tiotropium Respimat 5 mg 88 24  6 22  5 12.0e32.7 < 0.01
Twice-daily tiotropium Respimat 2.5 mg 89 23  6 21  5 11.1e31.6 < 0.01
Placebo Respimat 91 2  6
Pre-dose PEFpm, L/min
Once-daily tiotropium Respimat 5 mg 89 27  6 29  5 18.7e38.6 < 0.01
Twice-daily tiotropium Respimat 2.5 mg 89 28  6 30  5 20.0e39.8 < 0.01
Placebo Respimat 91 2  6
Full analysis set. At study baseline (randomisation, Visit 2), weekly mean PEFam and PEFpm were 373 L/min (SD 124 L/min) and 396 L/min
(SD 126 L/min), respectively.
CI, confidence interval; PEFam, morning peak expiratory flow; PEFpm, evening peak expiratory flow; SD, standard deviation; SE, standard
error.
a Adjusted for treatment, period, patients and baseline. Response defined as the change from the study baseline at randomisation
before the first inhalation of study drug.
336 W. Timmer et al.rate as a pre-defined primary end point has been con-
ducted, using an appropriate parallel-group design and 24-
week treatment duration [12,14].
Both tiotropium dosing regimens had a comparable 24-h
FEV1 profile that was superior to placebo. A diurnal varia-
tion in FEV1 response over 24 h was observed, with an in-
crease approximately 12 h after evening dosing in all
treatment groups, which indicates that this pattern is not a
consequence of tiotropium dosing. Rather, it is likely
attributable to a night-time increase, and subsequent
morning decrease, in parasympathetic activity with asso-
ciated changes in bronchodilation, as has been previously
reported in asthma clinical studies [9,16,17]. We note that
in the present study, all patients received morning and
evening ICS doses during each 4-week treatment period.
Once-daily dosing has been suggested to improve treat-
ment effectiveness in asthma. A number of studies have
shown that, compared with twice-daily dosing, once-daily
dosing of ICS improves patient adherence and is associated
with symptomatic benefit, improved quality of life and
reduced management costs [18e20]. Thus, relative to
twice-daily dosing, there is evidence to suggest that there
may be adherence benefits to be gained from dosing tio-
tropium once-daily. Further, once-daily tiotropium 5 mgTable 4 Tiotropium Respimat pharmacokinetic parameters at
Parameter Once-daily tiotropium Respimat 5 mg
n Geometric mean Geometr
AUC(0e24h),ss, pg$h/mL 0 e e
AUC(0et),ss, pg$h/mL 18 47.9 34.4
Cmax,ss, pg/mL 25 5.5 71.0
fe(0e24h),ss, % 28 13.1 104.0
Pharmacokinetic subset (30 patients).
AUC(0e24h),ss, area under the curve over 24 h at steady state; AUC(0et),
state (24 h and 12 h for tiotropium Respimat 5 mg and 2.5 mg, respec
coefficient of variation; fe(0e24h),ss, urinary excretion over 24 h at steadded to ICS  LABA has been shown to be efficacious when
administered in the morning [9,10] or the evening [11e13].
Conclusions
The observed improvements in lung function over 24 h with
tiotropium Respimat were sustained and comparable for
the once-daily 5 mg and twice-daily 2.5 mg dosing regimens.
These results support once-daily tiotropium Respimat 5 mg
as the appropriate dosing regimen as add-on to ICS in pa-
tients with symptomatic asthma.
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Table 5 Frequency of patients with adverse events that occurred in 1 patient in one treatment group overall.
n (%) Once-daily tiotropium
Respimat 5 mg (n Z 90)
Twice-daily tiotropium
Respimat 2.5 mg (n Z 90)
Placebo Respimat
(n Z 92)
Patients with any adverse event 22 (24.4) 26 (28.9) 26 (28.3)
Headache 5 (5.6) 7 (7.8) 4 (4.3)
Nasopharyngitis 3 (3.3) 3 (3.3) 4 (4.3)
Diarrhoea 3 (3.3) 1 (1.1) 1 (1.1)
Dry mouth 3 (3.3) 1 (1.1) 1 (1.1)
Respiratory tract infection viral 0 1 (1.1) 3 (3.3)
Dysphonia 0 2 (2.2) 2 (2.2)
Rhinitis 2 (2.2) 1 (1.1) 1 (1.1)
Cough 1 (1.1) 0 2 (2.2)
Nasal dryness 1 (1.1) 0 2 (2.2)
Influenza 0 2 (2.2) 0
Back pain 0 2 (2.2) 0
Sinus tachycardia 2 (2.2) 0 0
Hypertension 0 0 2 (2.2)
Bronchitis 0 1 (1.1) 1 (1.1)
Gastroenteritis 0 1 (1.1) 1 (1.1)
Sinusitis 0 1 (1.1) 1 (1.1)
Vomiting 1 (1.1) 1 (1.1) 0
Contusion 1 (1.1) 1 (1.1) 0
Asthma 0 1 (1.1) 1 (1.1)
Patients with a serious adverse event 2 (2.2) 0 1 (1.1)
Treated set.
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